Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials

Pain Medicine

Volumn 9, Issue 2, 2008, Pages 175-185

  Adelman, James ^a   Freitag, Fred G ^b   Lainez, Miguel ^c   Shi, Yingqi ^d   Ascher, Steven ^e   Mao, Lian ^e   Greenberg, Steven ^e   Hulihan, Joseph ^e  

^a Headache Wellness Center   (United States)

^b DIAMOND HEADACHE CLINIC   (United States)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^e Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Headache; Migraine; Topiramate

Indexed keywords

ACETYLSALICYLIC ACID; ERGOT DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PLACEBO; TOPIRAMATE; TRIPTAN DERIVATIVE;

ABDOMINAL PAIN; ABNORMAL VISION; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; ATTENTION DISTURBANCE; BACKACHE; BICARBONATE BLOOD LEVEL; BLOOD EXAMINATION; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM DISEASE; CHLORIDE BLOOD LEVEL; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; GASTROINTESTINAL DISEASE; GLAUCOMA; HUMAN; HYPERAMMONEMIA; HYPERTHERMIA; HYPESTHESIA; INJURY; INSOMNIA; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MEMORY DISORDER; MENTAL DISEASE; METABOLIC ACIDOSIS; METABOLIC DISORDER; MIGRAINE; MOOD DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROLITHIASIS; NEUROLOGIC EXAMINATION; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARYNGITIS; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SPEECH DISORDER; TASTE DISORDER; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; CHILD; CONTROLLED CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FRUCTOSE; HUMANS; MIDDLE AGED; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; PATIENT SELECTION; PLACEBOS; SAFETY;

EID: 39649084396     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2007.00389.x     Document Type: Article

References (22)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Results from the American Migraine Study II. Headache 2001;41:646-57.
2. Kruit MC, van Buchem MA, Hofman PAM, et al. Migraine as a risk factor for subclinical brain lesions. JAMA 2004;291:427-34.
3. Lipton RB, Liberman JN, Kolodner KB, et al. Migraine headache disability and health-related quality-of-life: A population-based case-control study from England. Cephalalgia 2003;23:441-50.
4. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache 2001;41:638-45.
5. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 1999;159:813-8.
6. Stang PE, Crown WH, Bizier R, Chatterton ML, White R. The family impact and costs of migraine. Am J Manag Care 2004;10:313-20.
7. Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Cur Med Res Opin 2001;17:S4-12.
8. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994;28:659-64.
9. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002;59:1011-24.
10. Snow V, Weiss K, Wall EM, Mottur-Pilson C, for the American Academy of Physicians and the American College of Physicians-American Society of Internal Medicine. Pharmacologic management of acute migraine attacks of migraine and prevention of migraine headache. Ann Intern Med 2002;137:840-9.
11. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-Based Guidelines for Migraine Headache in the Primary Care Setting: Pharmacological Management for Prevention of Migraine. 2000. Available at: http://www.aan.com/professionals/practice/pdfs/gl0090.pdf (accessed January 2005).
12. Geraud G, Lanteri-Minet M, Lucas C, Valade D. French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004;26:1305-18.
13. Dowson AJ, Lipscombe S, Sender J, Rees T, Watson D, MIPCA Migraine Guideline Development Group. Migraine in Primary Care Advisors. New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002;18:414-39.
14. Loder E, Silberstein S, Diamond S, etal. Candidates for preventive migraine therapy in a community sample: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Presented at the 58th Annual Meeting of the American Academy of Neurology, April 1-8, 2006, San Diego, CA.
15. Headache Classification Committee of the International Headache Society. The International classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(suppl 1):9-160.
16. Silberstein SD, Neto W, Schmitt J, Jacobs D, for the MIGR-001 Study Group. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol 2004;61:490-5.
17. Brandes JL, Saper JR, Diamond M, et al., for the MIGR-002 Study Group. Topiramate for migraine prevention. A randomized controlled trial. JAMA 2004;291:965-73.
18. Diener HC, Tfelt-Hansen P, Dalhöf C, et al., on behalf of the MIGR-003 Study Group. Topiramate in migraine prophylaxis. Results from a placebo-controlled trial with propanolol as an active control. J Neurol 2004;251:943-50.
19. Bussone G, Diener HC, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: A pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005;59:961-8.
20. Doose DR, Wang S-S, Padmanabhan P, et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and non-obese female subjects. Epilepsia 2003;44:540-9.
21. Young WB, Rozen TD. Preventive treatment of migraine: Effect on weight. Cephalalgia 2004;25:1-11.
22. Cady R, Dodick DW. Diagnosis and treatment of migraine. Mayo Clin Proc 2002;77:255-61.